The U.S. House of Representatives passed the INVEST Act, a BIO‑backed bipartisan bill designed to unlock capital for small, innovative firms by removing regulatory hurdles for companies and investors. Lawmakers and industry leaders said the package bundles measures that shore up early‑stage funding, tax incentives and ownership reforms intended to improve the investment climate for startups. BIO praised the bill as crucial to helping small biotech bridge the gap between discovery and commercialization, and coalition letters accompanying the vote argued the measures will accelerate development of new therapies. The bill passed the House by a wide margin and now moves to the Senate for consideration. If enacted, the INVEST Act could materially affect financing dynamics across the biotech sector by reducing barriers to capital formation and broadening investor participation in emerging life‑science companies.